TEVJFOTCinactive

TEVA PHARMACEUTICAL INDUSTRIES LTD

Healthcare·Oncology·Phase 3·Tel Aviv-Yafo, Israel
OncologyImmunology

TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVJF): 2 pipeline candidates · 2 clinical trials. Updated within the last hour.

6.6/10

BioSniper Score

2-factor signal · derived from public data

Cash RunwayN/A

N/A

Financial HealthN/A

N/A

Pipeline Maturity8.5

Lead: Phase 3

Pipeline Breadth4.6

2 candidates

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for TEVA PHARMACEUTICAL INDUSTRIES LTDacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$35.3B

Cash

Quarterly Burn

Runway

Revenue

Pipeline (2 candidates)

2 clinical trials·CEO: Mr. Richard D. Francis

Frequently asked questions

How many drug candidates are in TEVA PHARMACEUTICAL INDUSTRIES LTD's pipeline?

TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVJF) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is TEVA PHARMACEUTICAL INDUSTRIES LTD's lead drug candidate?

TEVA PHARMACEUTICAL INDUSTRIES LTD's most advanced tracked candidate is tapinarof cream 1% (Phase 3) for Plaque Type Psorisis.

What is TEVA PHARMACEUTICAL INDUSTRIES LTD's market capitalization?

TEVA PHARMACEUTICAL INDUSTRIES LTD's market capitalization is approximately $35.3B.

Who is the CEO of TEVA PHARMACEUTICAL INDUSTRIES LTD?

Mr. Richard D. Francis is the chief executive officer of TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVJF).

Get the full picture on TEVA PHARMACEUTICAL INDUSTRIES LTD

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.